Fluvoxamine (FVX) can be reduced at a mercury-drop electrode, with a maximum peak current intensity being obtained at a potential of -0.7 V vs. Ag/ AgCl, in an aqueous electrolyte solution of pH 2. The compound was determined in a pharmaceutical product and in spiked human serum by square-wave adsorptivestripping voltammetry (SWAdSV) after accumulation at the electrode surface, under batch conditions. Because the presence of dissolved oxygen did not interfere significantly with the analysis, it was also possible to determine FVX in the pharmaceutical product by use of a flow-injection analysis (FIA) system with SWAdSV detection. The methods developed were validated and successfully applied to the quantification of FVX in a pharmaceutical product. Recoveries between 76 and 89% were obtained in serum analysis. The FIASWAdSV method enabled analysis of up to 120 samples per hour at reduced cost, implying the possibility of competing with the chromatographic methods usually used for this analysis.
Introduction
Fluvoxamine (FVX, Fig. 1 ), a selective serotonin re-uptake inhibitor (SSRI), is primarily used as an antide-pressant drug but is also used to treat other psycholog-ical problems, for example obsessive-compulsive, panic, and post-traumatic stress disorders.
For drug development and for treatment purposes it is very important to be able to quantify the drug, and occasionally its metabolites, in a wide variety of samples (serum, plasma, urine, and pharmaceutical products) to establish its pharmacokinetics, metabolic pathway, dosage, etc. This implies the need for analytical methods with high sample-throughput, low limits of detection, and low maintenance costs.
After administration, FVX is extensively metabolised in the liver, without formation of active metabolites, and only negligible amounts are excreted unchanged in the urine. Its concentration in blood is difficult to predict, because of high variability between individuals, and no therapeutic window has been established [1] [2] [3] . Thus, therapeutic drug monitoring might be helpful to im-prove therapy with FVX.
Most FVX analysis is performed by high-perfor-mance liquid chromatography (HPLC) coupled with spectrometric detectors, ultraviolet/diode array [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] , mass spectrometric [18, 19] and fluorimetric [20] [21] [22] , for analysis of pharmaceuticals [8] and human serum or plasma [4] [5] [6] [7] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . This widespread usage of HPLC methods is justified by the high sensitivity and the low limit of detection usually obtained and the possibility of simultaneous analysis of the drug and its metabolites, which increases its use even further. The main disad-vantages of HPLC are the relatively long analysis times and high acquisition and maintenance costs. Several other methods, based on electrophoresis [23, 24] , micellar electrokinetic capillary chromatography [25] , isotachophoresis [26] , gas chromatography [27] [28] [29] [30] , ultraviolet-visible [31] [32] [33] [34] [35] [36] , infrared [31] , and nuclear magnetic resonance [31, 37] spectrometry, have also --1 Fig. 1 Chemical structure of FVX been described, mainly for determination of FVX in pharmaceutical products.
Electrochemical studies on the determination of FVX have also been reported [38] [39] [40] . All these studies focussed on the determination of the antidepressant in pharmaceutical products using either square-wave or differential-pulse polarography under batch conditions. Adsorptive-stripping voltammetry (AdSV) is a tech-nique mainly used for the analysis of organic com-pounds, which can be accumulated at, for example, the hanging mercury drop electrode (HMDE) surface and afterwards stripped off by applying a potential scan [41] . The introduction of highscan-rate voltammetric tech-niques, for example squarewave voltammetry (SWV), increases the sensitivity of AdSV even further [42, 43] .
In this study electroanalytical procedures for the determination of FVX in a pharmaceutical product and in spiked human serum under batch conditions are presented. Furthermore, an alternative method for determination of FVX in a pharmaceutical product has also been developed by adapting a square-wave-strip-ping voltammetric method for use in a FIA system.
Experimental Apparatus
Voltammetric measurements, using SWV and squarewave adsorptive-stripping voltammetry (SWAdSV), were performed using a Autolab PGSTAT12 (MetrohmEcoChemie) potentiostat, controlled by a PC by use of GPES 4.9 software from Metrohm-EcoChemie, and a Metrohm 663 VA stand containing a three-electrode cell (all Metrohm). This voltammetric cell consisted of a multimode mercury working electrode, used in the static mercury-drop position (SMDE), an Ag/AgCl/KCl 3 mol L -1 reference electrode, and a glassy carbon auxiliary electrode. This system was used both under batch conditions and as the detector in the developed single FIA manifold.
In the FIA system the solutions were transported to the voltammetric detection cell by means of a Gilson Minipuls 3 peristaltic pump, using PTFE tubing (i.d. 0.8 mm). Samples and standards (Vinj=500 lL) were introduced into the carrier stream through a six-port Rheodyne type 5041 injection valve.
In the voltammetric flow cell used [44] the glass capillary of the SMDE is inserted into a PTFE adapter head and the flow is directed toward the mercury drop.
This adapter head enables reproducible repositioning of the glass capillary whenever the flow cell is dismounted and then remounted. The adapter head, the reference electrode, and the counter-electrode are contained in a glass cell, which is filled with the solution used as the carrier stream. A drain ensures a constant level of solution is maintained during the work.
The comparative UV spectrophotometric method, using a Shimadzu UV-260 recording spectrophotometer, was developed internally by recording the absorption spectrum of a 5.0·10
-5 mol L -1 FVX solution between 190 and 360 nm. The absorbance peak at 245 nm was selected for quantification purposes.
Reagents
An FVX maleate standard was provided by Solvay Pharmaceuticals (Olst, The Netherlands) and used without further purification. Stock solutions of FVX were prepared by dissolution of precisely weighed amounts of the standard in water. These stock solutions were diluted with electrolyte solution to furnish the desired concentration. All other reagents, of p.a. quality, were purchased from Merck and Sigma-Aldrich. All solutions were prepared using deionised water (conductivity <0.1 lS cm -1 ). For optimisation of electrolyte pH, several buffers, for example phosphate, acetate, and ammonium, were used to cover a wide pH range (2-10). After optimisa-tion pH 2 H3PO4/H2PO4 buffer (0.1 mol L ) was used.
Samples
The pharmaceutical used for evaluation of the adequacy of the developed method was Dumyrox (Solvay Pharmaceuticals). This is currently the only commercially available FVX-containing pharmaceutical on the Portuguese market. The labelled value of FVX maleate per tablet is 50 mg. The tablets were weighed, finely powdered, and dissolved in 500.0 mL deionised water by sonication for 10 min.
For batch analysis the resulting solution was diluted 100-fold with electrolyte. For quantification purposes, using the standard addition method, fixed volumes (117 lL) of the diluted sample solution were placed in five 20.00-mL volumetric flasks and standard additions between 0 and 1.20·10 -8 mol L -1 were made by adding increasing quantities of FVX standard. The volume was completed with electrolyte and the contents of the volumetric flasks were transferred into a voltammetric cell and analysed.
For the standard addition method in the flow-injection technique six standards were prepared by placing 21.7-lL samples in 10.00-mL volumetric flasks and standard additions between 0 and 1.00·10 -6 mol L -1
were made by adding increasing quantities of FVX standard. The volume was completed with electrolyte and the solutions were then injected directly into the FIA system. For quantification by the comparative UV method five standard additions between 0 and 4.00·10 -5 mol L -1 were made to 1.000 mL of the sample solution contained in a 10.00-mL volumetric flask. The volume was completed with water and the solutions were filtered before analysis.
Serum samples were obtained from healthy individuals who were not receiving treatment with FVX, and analysed on the same day. This serum (1.000 mL) was spiked with an amount of FVX giving a concentration approximately five times the therapeutic level (1.6·10 -6 mol L -1 ). After shaking, 1.5 mL NH4Cl/NH3 buffer solution, pH 9.5, was added. The mixture was shaken mechanically for 30 s then extracted with chloroform-2-isopropanol-n-heptane, 60:14:26 (v/v). After shaking for 2 min and centrifuging for 10 min at 2800g, the organic layer was transferred to another receptacle and evaporated under a stream of nitrogen [10] . The dried extract was dissolved in 5.000 mL electrolyte and a 923-lL portion was added to 20.00 mL electrolyte in the voltammetric cell to furnish a concentration of 1.5·10 -8 mol L -1 . Again, the standard addition method was used, and the additions, between 0 and 3.02·10 -8 mol L -1 , were made directly in the voltammetric cell.
Validation procedure
When the optimum experimental conditions had been found, validation of the methods was performed. For this purpose, the linear range, limit of detection (LOD), limit of quantification (LOQ), repeatability, intermedi-ate precision, recovery, and selectivity were evaluated [45] .
The linear range was determined by analysing FVX solutions in the ranges 1.00·10 -9 to 1.00·10 -6 mol L for the SWAdSV and FIA-SWAdSV methods, respectively. The LOD and LOQ were calculated from the linear calibration plot [46] . 
Results

Analysis of fluvoxamine using SWAdSV
The electrochemical behaviour of FVX was studied under batch conditions by SWV and SWAdSV and it was verified that the analytical signal obtained decreased with increasing electrolyte pH. A maximum peak current intensity (ip), with a good repeatability, was obtained at pH 2. At this pH FVX gave a reduction peak at approximately -0.7 V, which increased with increasing accumulation time (tacc) (Fig. 2,I ). For a 1·10 -8 mol L -1 FVX solution this increase is significant for up to approximately 2 min (Fig. 2,II) at an optimised accumulation potential (Eacc) of -0.5 V, after which the increase of ip levels off, possibly because of In the application of the SWAdSV method to the quantification of FVX in Dumyrox, analyses were performed using a standard addition interval between 0 and 1.20·10 -8 mol L -1 and a tacc of 30 s. The result obtained, 50.3±1.3 mg FVX maleate/tablet (n=3), was in good agreement with the labelled value (50 mg FVX maleate/tablet) and with the result provided by the comparative UV method, 51.6±1.0 mg FVX maleate/ tablet (n=3). Table 2 shows the results obtained from application of the method to quantify FVX in six spiked serum samples, using standard additions and f of 50 Hz. The recovery was calculated to assess the accuracy of the method. Figure 3 shows the voltammograms obtained from a typical FVX analysis in human serum. The possibility of avoiding time-consuming deoxygenation of the analysed solution was also studied. It was observed that dissolved oxygen did not interfere significantly when tacc was 30 s (Eacc=-0.5 V), even when low frequencies and concentrations (10 -8 mol L -1 ) were used (Fig. 4) . The possibility of performing the measurements without the previous deoxygenation step enables signif-icant reduction of the analysis time and the possibility of including the HMDE in an FIA system, without prior or on-line oxygen removal, which leads to an increase in sample throughput.
Analysis of fluvoxamine using FIA-SWAdSV
On the basis of the previous results a single-manifold FIA system was developed in which the adsorption step at the HMDE was performed while the sample solution slug was flowing through the adapter head containing the mercury electrode [44] . The square wave voltam- It was shown that flow rates up to about 1.4 mL min -1 had no significant effect on ip but that repeatability decreased slightly with increasing flow rate. A flow rate of 1.1 mL min -1 was regarded as adequate for analysis of FVX, being a good compromise between sample throughput and repeatability. Using this flow rate, an injection volume of 500 lL and a tube length of 50 cm between the injector and the detector, a constant concentration profile between ±20 and 35 s after injection was obtained (Fig. 5) . The length of this zone depends on the injection volume and the flow rate, which can easily be controlled. The adsorption step and the voltammetric scan should be performed within this time interval.
By performing accumulation and measurement in the established interval, several experimental conditions of the voltammetric detection system were gradually opti-mised to obtain maximum sensitivity, repeatability and high sample throughput. The optimum Eacc was found to be -0.6 V, at which an increase of tacc from 0 to 5 s led to a marked increase of ip. For longer tacc (up to 10 s) ip levels off, possibly because of saturation coverage of the drop, competitive adsorption, or removal of species by the flow. A tacc of 5 s was regarded as suitable for use. Up to 120 samples per hour could be analysed using the proposed flow system.
Several frequencies (50-400 Hz), DEs (1-11 mV), and DEp (10-60 mV) were studied. The optimum conditions for determination of FVX were established as f=250 Hz, DEs=7 mV, and DEp=30 mV.
Variation Ta-ble 3 ; they imply the method is precise. From the recovery values shown in Table 3 it can be concluded that the method is accurate and selective for FVX determination.
To evaluate the adequacy of the method it was applied to the quantification of FVX in Dumyrox. Typical flow-injection voltammograms obtained during quantification of FVX in Dumyrox are shown in Fig. 6 . The result, 55.0±2.2 mg FVX maleate/tablet (n=3), is in good agreement with the labelled value (50 mg FVX maleate/tablet) and with the result obtained from a UV method used for comparison, 54.4±4.1 mg FVX maleate/tablet (n=3). 
Conclusions
On the basis of the electrochemical behaviour of FVX, SWAdSV and FIA-SWAdSV analytical methods have been developed for quantification of the drug in a pharmaceutical product and in spiked human serum. Both methods can be applied as good alternatives to the chromatographic methods used for determination of FVX in pharmaceutical preparations. For quantification of FVX in serum further optimisation is needed to compete with the techniques most widely used for this analysis. Both methods have the advantages of high sample throughput and significantly reducing analysis time and cost.
Further investigation is being undertaken to determine FVX in biological samples using on-line sample extraction and the HMDE flow cell as an HPLC detector.
